![](https://vistapglobal.com/wp-content/uploads/2021/05/pexels-thirdman-5921729.jpg)
As per reports, Walgreen Boots Alliance (WBA) has administered more than 20 million COVID-19 vaccinations as of May 24 closer to the target of about 30 million shots this year. The company has also done more than 8 million COVID-19 tests, informed Walgreens senior vice president Rick Gates.
On March 31, Walgreens raised its outlook for earnings for the year ended Sept. 30 and relied on administering 26 million to 34 million COVID-19 vaccine doses in 2021. As COVID-19 cases in the United States reduce to levels not seen since March of 2020, Americans go off masks and abandon social distancing protocols. The retail giant Walgreens is watching for a return to a “more normal” cough and cold season this fall, informed Gates. The use of medicines to treat cough and cold will certainly go up in the fall, but whether demand returns to pre-pandemic levels will is still uncertain.
Walgreen Boots Alliance (WBA) is a pharmacy-led, health and well-being enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. To learn more about Walgreen Boots Alliance (WBA) and to continue to track its progress please visit the Vista Partners Walgreens Boots Alliance Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research